

Abacavir + dolutegravir + lamivudine  
Essential medicine status  
General description

INN  
Abacavir + dolutegravir + lamivudine  
ATC codes  
[J05AR13](#)

Medicine type  
Chemical agent  
EML status history

First added in 2025 ([TRS 1064](#)) for [Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

Wikipedia  
[Abacavir + dolutegravir + lamivudine](#)

DrugBank  
[Abacavir](#) ,  
[Dolutegravir](#) ,  
[Lamivudine](#)

Recommendations  
Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid > tablet: 60 mg (as sulfate) + 5 mg + 30 mg (dispersible, scored)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)